Search

OBJECTIVE: To investigate the effects of solasonine on the proliferative activity of hepatoma cells and the regulation of mitogen-activated protein kinase/extracellular signaling regulation kinase (MAPK/ERK) signaling pathway. METHODS: HepG2 cells in logarithmic growth phase were randomly divided into the control group, solasonine group (cells treated with 50 μmol/L solasonine), activator group (cells treated with 20 μmol/L ISO) and activator + solasonine group (cells treated with 50 μmol/L solasonine after 24 h of treatment with 20 μmol/L ISO). After 24 h, MTT assay was used to detect cell viability, scratch assay was used to detect cell migration, transwell assay was used to detect cell invasion, and Western blotting was used to detect the relative expression levels of p-ERK, ERK, mitogen activated protein kinase kinase (MEK) and p-MEK protein. RESULTS: Compared with the 0 μmol/L solasonine group, the cell viability of 10, 20, 30, 40 and 50 μmol/L solasonine group decreased significantly (P< 0. 05), the difference was concentration-dependent. Compared with the control group, the cell survival rate, scratch healing rate and relative expression levels of p-ERK and p-MEk protein and number of invasive cells in the solasonine group decreased, while the scratch healing rate and relative expression levels of p-ERK and p-MEk protein and number of invasive cells in the activator group increased, with statistically significant differences (P<0. 05). Compared with the solasonine group, the cell survival rate, scratch healing rate and relative expression levels of p-ERK and p-MEk protein and number of invasive cells increased in activator + solasonine group, with statistically significant difference (P<0. 05). Compared with the activator group, the cell survival rate, scratch healing rate and relative expression levels of p-ERK and p-MEk protein and number of invasive cells decreased in the activator + solasonine group, with statistically significant difference (P<0. 05). CONCLUSIONS: Solasonine can reduce the proliferation, migration and invasion of hepatocellular carcinoma cells, possibly by inhibiting MAPK/ERK signaling pathway. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To understand the drug-resistance evolution of Escherichia coli (E. coli) and correlation with defined daily dose system (DDDs) and antibiotics use density (AUD) of antibiotics in Yiyang Central Hospital (Hereinafter referred to as “the hospital”) during 2012-2016, so as to provide reference for the rational drug application in clinic. METHODS: Retrospective analysis was conducted on the changes of drug resistance rate of E. coli and the situation of DDDs and AUD in the same period during 2012-2016, and the correlation between drug resistance rate and DDDs and AUD were analyzed. RESULTS: During 2012-2016, the annual inspection of E. coli in the rale were 18. 13% (874/4 822 strain) , 20. 78% (1 183/5 692 strain), 20. 41% (947/4 639 strain), 23. 88% (752/3 149 strain) and 22. 96% (750/3 266 strain), and which were in an increasing tendency. The detection rale of ESBL <57.5%. The E. coli to ampicillin and eefazolin showed higher resistance rate, and to levofloxacin, ceftazidime showed relatively high resistance rale, yet the overall data showed a downward trend year by year. During 2012-2016, the DDDs of levofloxacin, cefoperazone sulbactam and piperacillin tazobaetam dominated the top 3 places, the r were respectively -0. 129, -0.609 and -0.709. The AUD of levofloxacin, cefoperazone sulbactam and piperacillin tazobaetam were relatively high, the r were respectively 0. 329, -0. 282 and -0. 600. CONCLUSIONS: The tendency of antibiotic resistance in E. coli of die hospital has been checked, die application of antibiotics become more standard. It is necessary to strengthen the intervention on die whole application of antibiotics, so as to achieve the maximum efficiency, delay the development of bacterial resistance, and promote the rational application of drugs. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE:To probe into the clinical efficacy of pemetrexed combined with oxaliplatin in treatment of advanced colorectal cancer .METHODS: 100 patients with advanced colorectal cancer admitted into 242 Hospital of Shenyang from Oct .2013 to Jan.2014 were selected to be divided into observation group and control group via the random number table , with 50 cases in each .The control group were treated with oxaliplatin combined with fluorouracil , while the observation group received pemetrexed combined with oxaliplatin .The clinical treatment effects of two groups were observed and compared .RESULTS:After treatment , the remission rate of observation group was significantly higher than that of control group , the tumor endocrine indicators and unhealthy emotions of observation group was significantly better than that of control group , with statistically significant difference ( P<0.05 ) .After follow-up of one year , the survival rate of observation group was 10%( 5/50 ) , and control group was 2% ( 1/50 ) , with statistically significant difference ( P<0.05) .CONCLUSIONS:The efficacy of pemetrexed combined with oxaliplatin in treatment of advanced colorectal cancer is remarkable , which is worthy of clinical application and promotion [ABSTRACT FROM AUTHOR]